Want to see NIKI full AI Analyst Report?
NIKI Stock Chart & Stats
$8.38
-$0.20(-2.33%)
At close: 4:00 PM EDT
$8.38
-$0.20(-2.33%)
Day’s Range― - ―
52-Week Range$6.00 - $44.70
Previous CloseN/A
Volume50.61K
Average Volume (3M)113.32K
Market Cap
$8.04M
Enterprise Value-$2.15
Total Cash (Recent Filing)$3.45M
Total Debt (Recent Filing)$3.44M
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Sep 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.20
Shares Outstanding634,682
10 Day Avg. Volume164,850
30 Day Avg. Volume113,319
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)0.34
Price to Sales (P/S)0.00
P/FCF Ratio-4.24
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)31
Revenue Forecast (FY)$106.80M
Bulls Say, Bears Say
Bulls Say
Supportive Balance SheetImproved leverage and a sizable equity base provide a durable financial cushion for a development-stage biotech. This reduces near-term liquidation risk, supports continued R&D spending without immediate distress, and lengthens runway versus peers with weaker balance sheets, though financing may still be needed.
Improving Cash Burn TrendA declining cash burn trajectory and recent positive free cash flow growth represent a meaningful structural improvement. Slower cash outflows extend operational runway, lower the frequency of capital raises, and make program execution more feasible over months, reducing financing pressure if trends persist.
Asset Monetization Business ModelA clear strategy to create value by advancing candidates and monetizing via partnerships, licensing, or out-licensing is durable for a clinical-stage biotech. Successful collaborations can deliver non-dilutive funding, de-risk development, and provide commercialization pathways if clinical milestones are met.
Bears Say
Effectively Zero RevenueNear-zero recurring revenue is a structural weakness for sustaining operations without external financing. Lack of commercial sales means no internal cash generation to fund development, increases reliance on milestone/licensing events or fundraises, and raises execution risk over the next several months.
Persistent Operating LossesSustained operating and net losses erode equity and constrain reinvestment capacity. Continued negative earnings increase the probability of dilution or debt, impair long-term return metrics, and limit the firm’s ability to scale programs without crystallizing shareholder value loss.
Reliance On External FundingChronic negative operating cash flow necessitates periodic capital raises or partnerships, exposing the company to market timing and dilution risk. This reliance can disrupt development timelines if funding conditions tighten, and it structurally increases execution uncertainty for pipeline advancement.
NIKI FAQ
What was Niki BioSolutions Inc’s price range in the past 12 months?
Niki BioSolutions Inc lowest stock price was $6.00 and its highest was $44.70 in the past 12 months.
What is Niki BioSolutions Inc’s market cap?
Niki BioSolutions Inc’s market cap is $8.04M.
When is Niki BioSolutions Inc’s upcoming earnings report date?
Niki BioSolutions Inc’s upcoming earnings report date is Sep 15, 2026 which is in 41 days.
How were Niki BioSolutions Inc’s earnings last quarter?
Currently, no data Available
Is Niki BioSolutions Inc overvalued?
According to Wall Street analysts Niki BioSolutions Inc’s price is currently Overvalued.
Does Niki BioSolutions Inc pay dividends?
Niki BioSolutions Inc does not currently pay dividends.
What is Niki BioSolutions Inc’s EPS estimate?
Niki BioSolutions Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Niki BioSolutions Inc have?
Niki BioSolutions Inc has 634,682 shares outstanding.
What happened to Niki BioSolutions Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Niki BioSolutions Inc?
Currently, no hedge funds are holding shares in NIKI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Niki BioSolutions Inc
Aptorum Group Limited (APM) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutic candidates for diseases with significant unmet medical need. The company’s activities center on drug discovery and development, including preclinical and clinical advancement of product candidates, with an emphasis on areas such as infectious diseases and oncology. Aptorum also engages in strategies intended to accelerate development, which may include in-licensing, out-licensing, and collaborations related to its pipeline assets.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.22% Other Institutional Investors
99.78% Public Companies and
Individual Investors